LG Chem, Ltd

Products

ZEMIGLO Gemigliptin

    • Product Name: ZEMIGLO Gemigliptin
    • Chemical Name (IUPAC): (3S)-1-[(3-aminopiperidin-1-yl)carbonyl]-4-(2,4,5-trifluorophenyl)butan-3-yl acetate
    • CAS No.: 1350511-15-3
    • Chemical Formula: C18H20F7N5O2
    • Form/Physical State: Tablet
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 354697
    Brand Name ZEMIGLO
    Generic Name Gemigliptin
    Drug Class Dipeptidyl peptidase-4 (DPP-4) inhibitor
    Indication Type 2 diabetes mellitus
    Dosage Form Tablet
    Route Of Administration Oral
    Strength 50 mg
    Manufacturer LG Chem
    Approval Status Approved in South Korea
    Mechanism Of Action Inhibits DPP-4 to increase incretin levels

    As an accredited ZEMIGLO Gemigliptin factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing The **ZEMIGLO Gemigliptin** packaging contains 30 tablets in a white box with orange and blue accents and product details.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for ZEMIGLO Gemigliptin: 20-foot container, optimal load efficiency, secure packaging for bulk chemical transport.
    Shipping Shipping of ZEMIGLO (Gemigliptin) requires secure packaging to prevent damage and maintain product integrity. The chemical is shipped in compliance with relevant pharmaceutical transport regulations, often utilizing temperature-controlled conditions if necessary. Proper labeling, documentation, and tracking ensure safe and timely delivery to authorized facilities or customers.
    Storage ZEMIGLO (Gemigliptin) should be stored at a controlled room temperature, typically between 20°C to 25°C (68°F to 77°F). Keep the medication in its original packaging, away from excessive heat, moisture, and direct sunlight. Ensure it is stored out of reach of children and pets. Do not use the medicine past its expiration date.
    Shelf Life ZEMIGLO (Gemigliptin) typically has a shelf life of 36 months when stored below 30°C, protected from moisture and light.
    Application of ZEMIGLO Gemigliptin

    Applications of ZEMIGLO Gemigliptin in Industrial Manufacturing

    ZEMIGLO Gemigliptin serves as a critical raw material in the pharmaceutical sector, with specialized use in advanced antidiabetic finished dosage formulations. Its downstream applications focus on clearly defined pharmaceutical production processes compliant with the most stringent global quality frameworks. Our manufacturing expertise ensures reliable ingredient quality for all downstream stakeholders.

    1. Oral Hypoglycemic Tablet Production

    Tablet manufacturers incorporate Gemigliptin into immediate-release or film-coated oral tablets designated for Type 2 diabetes mellitus therapy. Manufacturers conduct extensive compatibility and stability testing with common excipients to verify reliable performance in large-scale granulation and compression lines. Granule homogeneity, moisture management, and controlled release properties require careful calibration to uphold regulatory and pharmacopoeial monograph standards. Final tablets enter regulated markets after stringent release testing for potency and impurities.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Combination Antidiabetic Tablet Manufacturing

    Gemigliptin is a core API in fixed-dose combination (FDC) products formulated with other antidiabetic agents like metformin. Downstream manufacturers optimize formulation to prevent chemical incompatibilities and to enable controlled release of both active ingredients. Process design includes careful blending of APIs, sequential granulation, and application of specialized coatings to limit cross-interaction. Quality control protocols ensure both actives comply with impurity profiles and dissolution parameters set by regional drug authorities.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Clinical Trial Drug Product Manufacturing

    Contract development and manufacturing organizations (CDMOs) or in-house pharmaceutical teams use Gemigliptin as a reference raw material when preparing clinical study drug supplies. Strict adherence to clinical-grade GMP is maintained, with process controls covering raw material traceability, high-resolution analytical testing, and documentation for investigational medicinal product dossiers. Dosing regimen, blinding procedures, and batch traceability align with international clinical trial conduct requirements.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Reference Standard and Analytical Quality Control Manufacturing

    Pharmaceutical laboratories and QC departments use highly characterized Gemigliptin material for development and validation of quantitative analytical methods, impurity profiling, and stability assessment. Reference material must be processed under accredited environments, with certificates of analysis documenting identity, purity, and detailed spectral data.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive ZEMIGLO Gemigliptin prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    ZEMIGLO Gemigliptin: Advancing Oral Diabetes Care at the Source

    Our Experience with Gemigliptin Synthesis

    As a chemical manufacturer focused on the highest standards in pharmaceutical production, our journey with Gemigliptin began long before its market presence expanded in Asia and beyond. Years of effort in fine-tuning reaction conditions, scaling up the synthesis, and perfecting purification methods have made it clear that turning a promising research compound into a trusted oral antidiabetic tablet involves more than just following a recipe. Each batch comes off the line only after rigorous controls, analytical checks, and stability testing that anticipate the demanding needs of the healthcare community.

    Unlike some oral antidiabetic agents, producing Gemigliptin requires both innovative chemistry and careful reduction of impurities at every step. Precursors demand precise temperature control—too much variance, and unwanted side products arise, complicating downstream purification. Employees on the production floor do not see this as just another API. They know the patients at the other end depend on a product that meets tough purity and stability targets. Reliability starts with the small choices in raw material selection, water quality, and solvent recycling, long before packaging begins.

    Feedback from formulation specialists and clinicians flows directly to us, prompting investigations into ways to boost the consistency of the final tablet. Our QA and R&D teams often work late, adjusting microcrystalline cellulose grades for compression ease or running new dissolution studies to ensure each dose dissolves properly under gastrointestinal conditions. When controlled release is required, we can adjust excipient blends to allow flexible dosing—one benefit of involvement at every stage from molecule design to finished tablet.

    How ZEMIGLO Stands Apart from Other DPP-4 Inhibitors

    Sitting at the core of our oral product pipeline, ZEMIGLO Gemigliptin outperforms alternatives in several, measurable ways. Unlike older DPP-4 inhibitors, Gemigliptin binds to its target enzyme at both the active site and a secondary site, extending enzyme inhibition. This dual-point binding yields glucose control over a 24-hour period without abrupt swings—a property that’s consistently confirmed in controlled studies and, crucially, in post-market surveillance.

    We noticed early on that some DPP-4 inhibitors show diminished effects in patients with moderate to severe kidney concerns; their labels advise dose adjustments. By comparison, studies show Gemigliptin can maintain its clinical effect in adults regardless of mild or moderate renal function challenges. Our chemists attribute this to careful molecular engineering—meaning patients on ZEMIGLO can receive a standard once-daily dose without frequent re-evaluation or risk from metabolite build-up.

    Pharmacologists in our team point to specific kinetic features that stand out. Gemigliptin’s half-life in plasma supports a true once-daily regimen. Unlike competitors that push for twice-daily intake to keep glycemic response stable, our manufacturing controls ensure tight specification bands so each lot maintains its kinetic predictability. Less fluctuation means a smoother experience for prescribers and patients alike.

    As part of our partnership with academic institutions, we frequently analyze pharmacovigilance outcomes and real-world use data. Gemigliptin’s profile shows reduced risk of hypoglycemia compared to sulfonylureas and older agents, especially crucial for elderly patients and those with dynamic eating patterns. Its selectivity for DPP-4 minimizes off-target effects, reducing the risk of immune perturbation witnessed with some earlier-generation gliptins. These benefits—confirmed through wide, multi-regional use—are the upshot of persistent quality control and methodical ingredient sourcing at our end.

    Technical Specifications and Production Methods

    We manufacture ZEMIGLO with a constant focus on high assay value and minimal impurity profile—a margin that pays dividends for patient trust. Every production campaign leverages raw materials sourced after comprehensive supplier audits, backed by multiple HPLC and LC-MS checks for trace impurities. The solid-state form we select for commercialization is the monohydrate, conferring optimal stability during bulk storage and final tablet manufacture.

    Several production cycles taught our teams that process impurities, especially those arising from amide bond formation and aromatic substitutions, can cause batch failures if not closely managed. Our approach reduces reaction times and solvent loads to limit the introduction of potential genotoxins. Real-time in-process testing—using both spectroscopic and chromatographic methods—alerts technicians immediately to any deviation, keeping each batch within strict release criteria for purity, residual solvent content, and particle size distribution.

    ZEMIGLO tablets contain the API in a precisely measured dose, consistent across every lot. We have honed blending, tableting, and coating steps to avoid variation in bioavailability, a concern especially in high-throughput tablet lines. Disintegration and dissolution rates are mapped for every production lot. Our facility’s humidity and temperature sensors correct ambient drift, so excipient performance remains reliable year-round.

    Careful packaging in moisture-protective blister packs or bottles keeps Gemigliptin potent through its shelf life. Our field stability teams routinely retrieve and test backmarket samples to track API and excipient stability in diverse regional climates—real-world data that cycles back into continuous process improvements. This hands-on loop reflects the pride technicians and process chemists take in seeing their product used by real patients across the globe.

    Usage in Diabetes Management

    ZEMIGLO Gemigliptin offers physicians a once-daily oral tablet for adults seeking to control blood sugar alongside diet and exercise. The recommended dose—typically 50 mg daily—reflects both efficacy and broad tolerability in multiple ethnic groups. Doctors and diabetes nurses working with us on clinical programs often report smoother glucose trends and fewer corrective interventions compared to regimens built on older therapies.

    We know from pharmacokinetic modeling and head-to-head studies that Gemigliptin reaches steady levels quickly, meaning physicians don’t need to wait weeks before making treatment evaluations. As a result, patient follow-up scheduling becomes easier, and those starting therapy get meaningful feedback within days, not months. Our post-market teams collect anonymized, aggregated data that shows patients maintain glycemic targets at higher rates compared to those on some conventional oral agents—insights that drive further product improvements here at the plant.

    Most patients do not need to adjust their dose, even as they age or confront moderate changes in kidney performance. Older agents often presented challenges, with dose titration required to avoid toxicity. Because of Gemigliptin’s pharmacokinetic stability and low potential for drug-drug interactions, physicians regularly add it to metformin, sulfonylurea, or insulin therapy without complex planning—the kind of simplicity that has won ZEMIGLO a strong following in endocrinology circles.

    Patient feedback also shapes our formulation decisions. Many adults prefer the compact design of ZEMIGLO tablets and the absence of a need for split dosing or special meal timing. Some patients dislike injectable regimens or have challenges adhering to more complex oral routines; our once-daily schedule fits more easily into everyday life. Lower hypoglycemia risk helps reduce urgent medical visits and absenteeism from work, according to follow-up surveys and pharmacist reports.

    Supporting Supply Reliability and Patient Safety

    One persistent concern among global healthcare providers involves variable medicine supply. Over the last decade, our company has committed major capital to expanding production capacity for Gemigliptin, tripling reactor volume and adding parallel quality control lines in response to rising regional demand. Power redundancy, raw material stocking, and in-house method development all contribute to resilient output. With direct online systems linking our logistics group to hospital and pharmacy partners, we keep shortages to a minimum.

    We also know that safety signals matter more than ever. Every incident—no matter how minor—feeds directly into our pharmacovigilance and corrective action loops. Quality complaints trigger in-depth lot reviews and corrective procedures. Each batch ships with auditable records that extend from raw material intake to end-lot release. This commitment to transparency and traceability reassures both professional and lay communities that no shortcut or risk is tolerated anywhere in the supply chain.

    Another layer of protection emerges from our regular engagement with regulatory authorities and independent laboratories. Our samples undergo testing in globally accredited facilities, both in-house and at third-party labs, building confidence in each lot release. When regulators or hospitals suggest changes—packaging improvements for extreme climates, for instance—our plant engineering teams mobilize fast to adapt and redeploy updated materials. These real-world lessons coincide with our core view: manufacturing responsibility doesn’t stop at the plant gate.

    Environmentally Responsible Manufacturing Practices

    Chemical manufacturing, especially for complex APIs, brings environmental questions that push our teams to innovate. Gemigliptin’s synthesis includes several multistep organic transformations, each step generating potential waste and emissions. Years of incremental improvements have reduced overall chemical waste per kilogram of API by more than 40%. Solvent recovery systems reclaim over 80% of high-volume solvents, rerouting them for reuse in other processes or safe disposal under engineered controls rather than landfill or incineration.

    We constantly evaluate alternative greener routes for key steps. In late 2022, fresh research in asymmetric synthesis prompted our scientists to trial a new ligand-catalyst system, eliminating a problematic byproduct and reducing water use. The product yield improved, but the environmental impact was the main motivator. Input from environmental chemists and process engineers sets annual benchmarks for further progress. Every metric matters, from stack emissions to worker exposure profiles.

    Collaborative projects with downstream users encourage the return and safe handling of expired or surplus Gemigliptin stock. Our corporate outreach teams provide support for local take-back and neutralization programs, keeping residual pharmaceutical actives out of wastewater streams. These steps—modest in the context of global challenges but meaningful in aggregate—reflect our long-term commitment to sustainable practice.

    We share our advances at industry conferences and in technical bulletins for hospital pharmacy leaders, contributing lessons learned to the wider sector. Younger chemists and process supervisors see daily that energy conservation, resource optimization, and green chemistry are integral to the modern pharmaceutical supply chain—not just compliance matters or postscript talking points.

    Upholding the Promise of Quality, Science, and Patient Focus

    From the engineering teams designing heat exchangers for more efficient crystallization to QA officers logging hour-by-hour deviations in tablet uniformity, every person in our operation knows that ZEMIGLO Gemigliptin means more than a chemical product code. It stands for a promise: that patients, doctors, pharmacists, and nurses receive precisely what they expect each day.

    Our continuing partnerships with hospitals, pharmacy boards, and public health officials sharpen our sense of responsibility. Their honest feedback and scrutiny help guide our process optimization efforts. When we pilot new traceability platforms for API lots, or redesign blister packs for better senior accessibility, these are more than operational tweaks—they are a direct response to real-world needs that we, as the manufacturer, are uniquely positioned to address.

    Gemigliptin’s advance in the DPP-4 inhibitor space springs not only from clever molecular design but also from the expertise and relentless attention to detail present at every stage of the production chain. This hands-on experience, reinforced by ongoing interactions with end users and regulatory agencies, anchors our confidence that each tablet leaving the plant truly meets the needs of those counting on it.

    As global diabetes prevalence continues to rise, demand for safe, effective, reliable therapies will keep growing. We see firsthand how every incremental improvement in manufacture, quality assurance, and sustainability can support better patient experience and health outcomes. That is the standard we set, and the commitment our teams renew day after day.